← All trials
NCT07212088
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2025
- Primary completion
- Nov 15, 2027
- Completion date
- Jun 15, 2028
- First posted
- Oct 8, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- iCamuno Biotherapeutics Ltd.Lead sponsor
- Zhejiang UniversityOfficial
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.